These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 28487044)

  • 1. Regional variation in the treatment of pancreatic adenocarcinoma: Decreasing disparities with multimodality therapy.
    Kasumova GG; Eskander MF; de Geus SWL; Neto MM; Tabatabaie O; Ng SC; Miksad RA; Mahadevan A; Rodrigue JR; Tseng JF
    Surgery; 2017 Aug; 162(2):275-284. PubMed ID: 28487044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trends in Receipt and Timing of Multimodality Therapy in Early-Stage Pancreatic Cancer.
    Dimou F; Sineshaw H; Parmar AD; Tamirisa NP; Jemal A; Riall TS
    J Gastrointest Surg; 2016 Jan; 20(1):93-103; discussion 103. PubMed ID: 26503262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multimodality therapy for pancreatic cancer in the U.S. : utilization, outcomes, and the effect of hospital volume.
    Bilimoria KY; Bentrem DJ; Ko CY; Tomlinson JS; Stewart AK; Winchester DP; Talamonti MS
    Cancer; 2007 Sep; 110(6):1227-34. PubMed ID: 17654662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Geographic disparities in surgical treatment recommendation patterns and survival for pancreatic adenocarcinoma.
    Salami A; Alvarez NH; Joshi ART
    HPB (Oxford); 2017 Nov; 19(11):1008-1015. PubMed ID: 28838634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trajectory of care and use of multimodality therapy in older patients with pancreatic adenocarcinoma.
    Parmar AD; Vargas GM; Tamirisa NP; Sheffield KM; Riall TS
    Surgery; 2014 Aug; 156(2):280-9. PubMed ID: 24851723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disparities in utilization of treatment for clinical stage I-II pancreatic adenocarcinoma by area socioeconomic status and race/ethnicity.
    Swords DS; Mulvihill SJ; Brooke BS; Skarda DE; Firpo MA; Scaife CL
    Surgery; 2019 Apr; 165(4):751-759. PubMed ID: 30551868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overall survival is increased among stage III pancreatic adenocarcinoma patients receiving neoadjuvant chemotherapy compared to surgery first and adjuvant chemotherapy: An intention to treat analysis of the National Cancer Database.
    Shubert CR; Bergquist JR; Groeschl RT; Habermann EB; Wilson PM; Truty MJ; Smoot RL; Kendrick ML; Nagorney DM; Farnell MB
    Surgery; 2016 Oct; 160(4):1080-1096. PubMed ID: 27522556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence for treatment and survival disparities by age in pancreatic adenocarcinoma: a population-based analysis.
    Amin S; Lucas AL; Frucht H
    Pancreas; 2013 Mar; 42(2):249-53. PubMed ID: 22836862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. External radiation is associated with limited improvement in overall survival in resected margin-negative stage IIB pancreatic adenocarcinoma.
    Kantor O; Talamonti MS; Lutfi W; Wang CH; Winchester DJ; Marsh R; Prinz RA; Baker MS
    Surgery; 2016 Dec; 160(6):1466-1476. PubMed ID: 27614417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Failure to comply with NCCN guidelines for the management of pancreatic cancer compromises outcomes.
    Visser BC; Ma Y; Zak Y; Poultsides GA; Norton JA; Rhoads KF
    HPB (Oxford); 2012 Aug; 14(8):539-47. PubMed ID: 22762402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Racial differences in cancer specialist consultation, treatment, and outcomes for locoregional pancreatic adenocarcinoma.
    Murphy MM; Simons JP; Ng SC; McDade TP; Smith JK; Shah SA; Zhou Z; Earle CC; Tseng JF
    Ann Surg Oncol; 2009 Nov; 16(11):2968-77. PubMed ID: 19669839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma.
    Glazer ES; Rashid OM; Pimiento JM; Hodul PJ; Malafa MP
    Surgery; 2016 Nov; 160(5):1288-1293. PubMed ID: 27450715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of radiotherapy with favorable prognosis in daily clinical practice for treatment of locally advanced and metastatic pancreatic cancer.
    Yang SH; Guo JC; Yeh KH; Tien YW; Cheng AL; Kuo SH
    J Gastroenterol Hepatol; 2016 Dec; 31(12):2004-2012. PubMed ID: 27059987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival impact of neoadjuvant therapy in resected pancreatic cancer: A Prospective Cohort Study involving 18,332 patients from the National Cancer Data Base.
    Mirkin KA; Hollenbeak CS; Wong J
    Int J Surg; 2016 Oct; 34():96-102. PubMed ID: 27573691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trends in the use of pre-operative radiation for adenocarcinoma of the pancreas in the United States.
    Burke EE; Marmor S; Portschy PR; Virnig BA; Cho LC; Tuttle TM; Jensen EH
    HPB (Oxford); 2015 Jun; 17(6):542-50. PubMed ID: 25726950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health Disparities Impact Expected Treatment of Pancreatic Ductal Adenocarcinoma Nationally.
    Lutfi W; Zenati MS; Zureikat AH; Zeh HJ; Hogg ME
    Ann Surg Oncol; 2018 Jul; 25(7):1860-1867. PubMed ID: 29691733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Associations of Socioeconomic Variables With Resection, Stage, and Survival in Patients With Early-Stage Pancreatic Cancer.
    Shapiro M; Chen Q; Huang Q; Boosalis VA; Yoon CH; Saund MS; Whang EE; Gold JS
    JAMA Surg; 2016 Apr; 151(4):338-45. PubMed ID: 26581025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes for patients with locally advanced pancreatic adenocarcinoma treated with stereotactic body radiation therapy versus conventionally fractionated radiation.
    Zhong J; Patel K; Switchenko J; Cassidy RJ; Hall WA; Gillespie T; Patel PR; Kooby D; Landry J
    Cancer; 2017 Sep; 123(18):3486-3493. PubMed ID: 28493288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of locally advanced pancreatic cancer in the real world: population-based practices and effectiveness.
    Krzyzanowska MK; Weeks JC; Earle CC
    J Clin Oncol; 2003 Sep; 21(18):3409-14. PubMed ID: 12972517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pancreatic resection: a key component to reducing racial disparities in pancreatic adenocarcinoma.
    Murphy MM; Simons JP; Hill JS; McDade TP; Chau Ng S; Whalen GF; Shah SA; Harrison LH; Tseng JF
    Cancer; 2009 Sep; 115(17):3979-90. PubMed ID: 19514091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.